SRM Case Study of Bristol-Myers Squibb Frances Grote, BMS Supplier relationship management
BMS instituted supplier relationship management in 2005 to work with their suppliers. They grew into a partnerships approach when working with their CROs. The companies needed added value, so they looked at supplier relationship management.
Key to success for supplier relationship management:
-Someone needs to be the driver. A group that is not the direct user of the services, and the ideas need to have a person to implement them, but isn’t’ there to get the job done. It’s a full time commitment, but after it’s in place, doesn’t need full time oversight.
-Senior leadership within business unit. They people who will use it need to buy in. They’re the stake holders and they’ll build your culture.
If someone sits in the suppliers side, that doesn’t mean that they’re another person. If it’s our project, they’re on your team. If you’re improving process, you’ll need to make improvement available to suppliers. If suppliers supply info to other customers, you’re receiving it as well. You all sell what you’ve created to the public, so share and benefit when you can.
If you do SRM well, you could become as important as you are to your suppliers. They’ll want to go back to you, if you have strong SRM, they’ll continue coming back to you. The governance success factors are that you do need committees, as they are key for relationship health but key to keeping internal people. Very strong issue escalation pathways. They need to know who to take it to, someone to hear it, and that’ll help them solve that problem.
Performance management:
- KPIs need to be tied to deliverables
- Deliverables based contracting seems to be key
- KPIs need to be tied to deliverables- Scorecards and KPIs are in place
At BMS, management changes that stayed because of MSAs (before SRM) not service level agreements but expectations about quality, governance. Neither side is up on all, but they’re there. SRM was in the philosophy, and it was more sophisticated. Governance proved to be very powerful. KPIs with metrics and score cards prove the data.
Search This Blog
Blog Archive
-
▼
2009
(141)
-
▼
April
(30)
- Inspirational Patient Perspective with NFL Legend ...
- Welcome to The Second and Final Day of the Conference
- Virtual Pharma: Addressing Challenges and Opportun...
- Understanding the Concepts of Disruptive Innovatio...
- Creating a Competitive Advantage through Sourcing
- Approaches to Address the Impact of Increasingly C...
- Clinical Trials: What Does Global Mean to You?
- MMAX: Development, Evolution, Growth and Maturatio...
- Leading Through Change: Innovation and the Future ...
- Wall Street’s 2009 Forecast and Analysis of Outsou...
- Live from the 18th Annual Partnerships with CROs
- Driving Global Growth: Strategic Considerations f...
- Governance and Supplier Relationship Management
- FierceBiotech is the Official Digital Media and Li...
- Speaker Profile: Peter B. Corr
- Speaker Profile: Harris Koffer, Pharm.D
- Speaker Profile: Christopher C. Gallen, MD, PhD
- Clinical trial begins for a malaria vaccine
- The Use of Bid Grids for Selecting a CRO as a Partner
- Partnerships with CROs April LinkedIn Update: Merg...
- Full Details are Required for Indian Clinical Trials
- Join us: Global Congress on Comparator Studies
- Partnerships with CROs & Other Outsourcing Provide...
- Patient recruitment costs continue to increase in ...
- Key Findings on CRO Industry
- France focuses on Clinical Trials
- CardioNet Expands into CRO Industry by Acquring Bi...
- The Political Economy of Pharmaceutical Clinical T...
- ICON teaming up with MedAvante
- New CenterWatch Report Examines Japan’s Surging Cl...
-
▼
April
(30)
No comments:
Post a Comment